Company Filing History:
3 out of 25 
1 out of 15 
1 out of 64 Years Active: 2023-2025
Title: The Innovative Contributions of Inventor Ji Hye Oh
Introduction: Ji Hye Oh is a distinguished inventor based in Daejeon, South Korea, known for his significant contributions to the field of biomedical innovations. With a remarkable portfolio of four registered patents, Ji Hye Oh has dedicated his career to developing compounds that have the potential to revolutionize cancer treatment.
Latest Patents: Ji Hye Oh's latest patents showcase his commitment to advancing medical science. One of his primary inventions is the "Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound," which is particularly geared towards anticancer applications. This innovative compound demonstrates excellent stability in both its intrinsic properties and plasma, enhancing its potential as a target-specific treatment for proliferative diseases like cancer. It effectively aims to maximize drug efficacy while minimizing side effects, making it a significant advancement in chemotherapy.
Moreover, he has developed compositions and methods related to "anti-CD19 antibody drug conjugates." This patent outlines a framework wherein active agents are conjugated to an anti-CD19 antibody via a linker, facilitating targeted therapeutic strategies. The invention encompasses various forms of monoclonal antibodies and their engineered fragments, highlighting their versatile applications across therapeutic, diagnostic, and prophylactic fields.
Career Highlights: Ji Hye Oh has worked with notable organizations such as Legochem Biosciences, Inc. and Abl Bio Inc., where he has honed his skills and developed groundbreaking healthcare solutions. His work within these firms has played a critical role in pushing the boundaries of current medical treatments, especially in oncology.
Collaborations: Throughout his career, Ji Hye Oh has collaborated with accomplished professionals including Ho Young Song and Sung Min Kim. These partnerships have fostered a productive environment for innovation, allowing for the pooling of expertise and resources in the pursuit of cutting-edge solutions to complex medical challenges.
Conclusion: Ji Hye Oh's innovations are a testament to the potential of targeted therapies in the fight against cancer. His patents not only exemplify his ingenuity but also reflect a broader commitment to enhancing human health through the development of advanced therapeutic modalities. As Ji Hye Oh continues to expand his research and collaboration efforts, the medical community eagerly anticipates the future impacts of his work.